ClinicalTrials.gg
CompletedNCT06400459Updated Feb 12, 2026Results posted

IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease

A Phase 1/2 interventional study of IVW-1001 Ophthalmic Eyelid Wipe 0.1% and IVW-1001 Ophthalmic Eyelid Wipe 0.2% in Dry Eye Disease, sponsored by IVIEW Therapeutics Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by IVIEW Therapeutics Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 544 studies in Dry Eye Syndromes with a site in United States — 52 open to participants now, 63 under way, 3 of them phase 3. Dry Eye Syndromes · United States.

Enrollment
139th of 473
150 · median 60
Started
2024
with 31 others
Phase 1/2
17 of 544
none open now
Registered
464th of 544
by date

Among the 544 studies in Dry Eye Syndromes with a site in United States, this one is the 139th largest by enrollment of the 473 interventional ones that give a count, is one of 32 that started in 2024, is one of 17 in phase 1/2, and was the 464th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

52 of the 544 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 544 studies in Dry Eye Syndromes with a site in United States, or all of them as a file.
02

Study summary

Double-masked, dose-response, trial of IVW-1001 in subjects with dry eye disease.

Read the detailed description

This is a randomized (1:1:1), multicenter, parallel, vehicle-controlled, double-masked study to evaluate the safety, tolerability, and efficacy of IVW-1001 Ophthalmic Eyelid Wipes in subjects with DED. Treatments will be IVW-1001 Ophthalmic Eyelid Wipe 0.2% (high dose), IVW 1001 0.1% (low dose), or IVW-1001 Ophthalmic Eyelid Wipe Placebo (vehicle). Subjects will participate in a 7-day, run-in period followed by a 28-daydosing period.

03

Conditions studied

  • Dry Eye Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects of any gender at least 18 years of age at the Screening Visit
  2. Able to voluntarily provide written to participate in the study
  3. Able and willing to comply with all study procedures and restrictions, follow study instructions, and complete required study visits
  4. Diagnosis of Dry Eye Disease (DED)

Exclusion criteria

Exclusion Criteria:

  1. Corneal fluorescein staining score of 4 using the NEI grading system
  2. Intraocular pressure ≥23 mmHg
  3. History of glaucoma or ocular hypertension in either eye requiring past or current medical or surgical intervention
  4. Subjects with ocular inflammatory conditions (eg, conjunctivitis, keratitis, severe anterior blepharitis, etc.) not related to DED
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    IVW-1001 0.1%

    IVW-1001 Ophthalmic Eyelid Wipe 0.1%

    Drug: IVW-1001 Ophthalmic Eyelid Wipe 0.1%

  • Experimental
    IVW-1001 0.2%

    IVW-1001 Ophthalmic Eyelid Wipe 0.1%

    Drug: IVW-1001 Ophthalmic Eyelid Wipe 0.2%

  • Placebo comparator
    IVW-1001 Placebo

    Vehicle

    Drug: IVW-1001 Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Schirmer's

    Mean change from baseline in study eye in unanesthetized measure of tear product using Schirmer strip (measured in mm of wetness)

    Time frame: 29 Days

Secondary outcomes

  1. Visual Acuity

    Mean change from baseline in best corrected visual acuity

    Time frame: 29 Days

  2. Total Corneal Fluorescein Staining Score in the Study Eye

    Change from baseline in score on a scale (0 - none - to 20 - severe)

    Time frame: Week 4

  3. Symptom Assessment in Dry Eye (SANDE): Frequency of Symptoms Score

    Change from Baseline in the SANDE visual analog scale (0 - none to 100 - severe)

    Time frame: Week 4

  4. Symptom Assessment in Dry Eye (SANDE): Severity of Symptoms Score

    Change from baseline in the SANDE visual analog scale (0 - none to 100 - severe)

    Time frame: 4 weeks

  5. Symptom Assessment in Dry Eye (SANDE): Global Score

    Change from baseline in the SANDE visual analog scale (0 - none to 100 - severe)

    Time frame: 4 weeks

07

Results

Posted Feb 12, 2026

Participant flow

Participant flow — Overall Study
MilestoneIVW-1001 0.1%IVW-1001 0.2%IVW-1001 Placebo
Started534849
Completed534849
Not completed000

Outcome measures

PrimarySchirmer's

Mean change from baseline in study eye in unanesthetized measure of tear product using Schirmer strip (measured in mm of wetness)

Time frame:
29 Days
Reported as:
Mean · mm
Schirmer's
mmIVW-1001 0.1%IVW-1001 0.2%IVW-1001 Placebo
Schirmer's1.3 ± 6.402.1 ± 6.640.9 ± 5.24
SecondaryVisual Acuity

Mean change from baseline in best corrected visual acuity

Time frame:
29 Days
Reported as:
Mean · Logarithm of Minimum Angle of Resolution
Visual Acuity
Logarithm of Minimum Angle of ResolutionIVW-1001 0.1%IVW-1001 0.2%IVW-1001 Placebo
Visual Acuity-0.007 ± 0.0739-0.013 ± 0.0625-0.014 ± 0.0728
SecondaryTotal Corneal Fluorescein Staining Score in the Study Eye

Change from baseline in score on a scale (0 - none - to 20 - severe)

Time frame:
Week 4
Reported as:
Mean · Score on a scale
Total Corneal Fluorescein Staining Score in the Study Eye
Score on a scaleIVW-1001 0.1%IVW-1001 0.2%IVW-1001 Placebo
Total Corneal Fluorescein Staining Score in the Study Eye-1.65 ± 0.24-1.80 ± 0.25-1.10 ± 0.25
SecondarySymptom Assessment in Dry Eye (SANDE): Frequency of Symptoms Score

Change from Baseline in the SANDE visual analog scale (0 - none to 100 - severe)

Time frame:
Week 4
Reported as:
Mean · Score on a scale
Symptom Assessment in Dry Eye (SANDE): Frequency of Symptoms Score
Score on a scaleIVW-1001 0.1%IVW-1001 0.2%IVW-1001 Placebo
Symptom Assessment in Dry Eye (SANDE): Frequency of Symptoms Score-5.77 ± 2.91-23.57 ± 3.06-9.88 ± 3.08
SecondarySymptom Assessment in Dry Eye (SANDE): Severity of Symptoms Score

Change from baseline in the SANDE visual analog scale (0 - none to 100 - severe)

Time frame:
4 weeks
Reported as:
Mean · Score on a scale
Symptom Assessment in Dry Eye (SANDE): Severity of Symptoms Score
Score on a scaleIVW-1001 0.1%IVW-1001 0.2%IVW-1001 Placebo
Symptom Assessment in Dry Eye (SANDE): Severity of Symptoms Score-8.73 ± 2.78-22.80 ± 2.93-12.55 ± 2.94
SecondarySymptom Assessment in Dry Eye (SANDE): Global Score

Change from baseline in the SANDE visual analog scale (0 - none to 100 - severe)

Time frame:
4 weeks
Reported as:
Mean · Score on a scale
Symptom Assessment in Dry Eye (SANDE): Global Score
Score on a scaleIVW-1001 0.1%IVW-1001 0.2%IVW-1001 Placebo
Symptom Assessment in Dry Eye (SANDE): Global Score-7.11 ± 2.70-23.36 ± 2.84-11.16 ± 2.86

Adverse events

Collected over Week 4. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IVW-1001 0.1%0/53 (0%)0/53 (0%)3/53 (5.7%)
IVW-1001 0.2%0/48 (0%)0/48 (0%)5/48 (10.4%)
IVW-1001 Placebo0/49 (0%)0/49 (0%)4/49 (8.2%)
Most frequent other events
Most frequent other events
EventIVW-1001 0.1%IVW-1001 0.2%IVW-1001 Placebo
Eye disordersEye disorders3/535/484/49

Baseline characteristics

Age, Continuous
Age, Continuous(years)IVW-1001 0.1%IVW-1001 0.2%IVW-1001 PlaceboTotal
Mean63.7 ± 11.1963.5 ± 12.0768.1 ± 11.4365.1 ± 11.57
Sex: Female, Male
Sex: Female, Male(Participants)IVW-1001 0.1%IVW-1001 0.2%IVW-1001 PlaceboTotal
Female363839113
Male17101037
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IVW-1001 0.1%IVW-1001 0.2%IVW-1001 PlaceboTotal
American Indian or Alaska Native0101
Asian1214
Native Hawaiian or Other Pacific Islander1012
Black or African American15111642
White363431101
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)IVW-1001 0.1%IVW-1001 0.2%IVW-1001 PlaceboTotal
United States534849150
Unanesthetized Schirmer test (Study Eye)
Unanesthetized Schirmer test (Study Eye)(mm)IVW-1001 0.1%IVW-1001 0.2%IVW-1001 PlaceboTotal
Mean6.8 ± 1.986.1 ± 1.876.7 ± 1.926.5 ± 1.93
Total Corneal Fluorescein Staining Score in the Study Eye (0, none to 20, severe)
Total Corneal Fluorescein Staining Score in the Study Eye (0, none to 20, severe)(Score on a scale)IVW-1001 0.1%IVW-1001 0.2%IVW-1001 PlaceboTotal
Mean6.5 ± 1.376.8 ± 1.726.8 ± 1.486.7 ± 1.53
Symptom Assessment in Dry Eye (SANDE): Frequency of Symptoms Score (0, none, to 100, severe)
Symptom Assessment in Dry Eye (SANDE): Frequency of Symptoms Score (0, none, to 100, severe)(Score on a scale)IVW-1001 0.1%IVW-1001 0.2%IVW-1001 PlaceboTotal
Mean61.1 ± 23.362.6 ± 21.161.9 ± 23.061.8 ± 22.5
Symptom Assessment in Dry Eye (SANDE): Severity of Symptoms Score
Symptom Assessment in Dry Eye (SANDE): Severity of Symptoms Score(Score on a scale)IVW-1001 0.1%IVW-1001 0.2%IVW-1001 PlaceboTotal
Mean54.9 ± 23.154.0 ± 20.255.0 ± 22.554.6 ± 21.9

1 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Houston Eye Associates
    Houston, Texas 77025, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Oct 2024, 3 months.

Results were first posted in Feb 2026, 1 year 3 months after primary completion.

Of 21 phase 1/2 interventional studies under Dry Eye Syndromes, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2024
First posted
May 6, 2024
StartActual
Jun 25, 2024
Primary completionActual
Oct 15, 2024
CompletionActual
Oct 15, 2024
Results first posted
Feb 12, 2026
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06400459
Lead sponsor
IVIEW Therapeutics Inc.
Responsible party
Sponsor
First posted
May 6, 2024
Start date
Jun 25, 2024
Primary completion
Oct 15, 2024
Completion
Oct 15, 2024
Results posted
Feb 12, 2026
Last update
Feb 12, 2026

Study contacts

Bo Liang, PhD
study director · IVIEW Therapeutics Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IVW-1001

Start the discussion